Economy Roche gets European approval for Tecentriq combo vs. lung cancer

Roche gets European approval for Tecentriq combo vs. lung cancer

Roche gets European approval for Tecentriq combo vs. lung cancer

Roche has received European Commission approval for its Tecentriq drug in combination with Avastin and chemotherapy as an initial treatment for people with a specific type of lung cancer, the Swiss pharma company said on Friday.

The combination has been approved as a first-line treatment for people with metastatic non-squamous non-small cell lung cancer (NSCLC).

NSCLC is the most common type of lung cancer, accounting for about 85 percent of all cases, Roche said.

Previous articleStopping work on Italy-France rail link would cost more than 3 billion euros
Next articleAir France KLM’s Feb passenger figures rise 4.1 percent year-over-year